Corbus Pharmaceuticals Holdings (CRBP) Capital Expenditures (2014 - 2024)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Capital Expenditures of $1000.0 for Q2 2024, up 100.47% quarter-over-quarter from -$213000.0 in Q1 2024.
Corbus Pharmaceuticals Holdings (CRBP) Capital Expenditures (2014 - 2024) Analysis & Trends
Corbus Pharmaceuticals Holdings' Capital Expenditures history runs 11 years deep, the most recent figure standing at $1000.0 for Q2 2024.
- In Q2 2024, Capital Expenditures changed N/A year-over-year to $1000.0; the TTM figure through Mar 2025 stood at $1000.0 (up 100.64% YoY), while the FY2024 annual figure was -$212000.0, down 471.93% from the prior year.
- Capital Expenditures for Q2 2024 stood at $1000.0, up from -$213000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $463605.0 in Q1 2020, with the low at -$213000.0 in Q1 2024.
- The 5-year median for Capital Expenditures is $14811.5 (2020), against an average of $39711.2.
- Peak annual rise in Capital Expenditures reached 529.77% in 2020, while the deepest fall reached 104.03% in 2020.
- Corbus Pharmaceuticals Holdings' Capital Expenditures stood at -$52086.0 in 2020, then surged by 204.0% to $54172.0 in 2021, then slumped by 75.17% to $13449.0 in 2022, then slipped by 18.21% to $11000.0 in 2023, then sank by 90.91% to $1000.0 in 2024.
- Business Quant data shows CRBP's Capital Expenditures at $1000.0 in Q2 2024, -$213000.0 in Q1 2024, and $11000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | -213,000.00 |
| Mar 31, 2024 | -213,000.00 |
| Dec 31, 2023 | 11,000.00 |
| Dec 31, 2023 | 11,000.00 |
| Sep 30, 2023 | 46,000.00 |
| Sep 30, 2023 | 46,000.00 |
| Mar 31, 2022 | 13,449.00 |
| Mar 31, 2022 | 13,449.00 |
| Dec 31, 2021 | 54,172.00 |
| Dec 31, 2021 | 54,172.00 |
| Dec 31, 2020 | -52,086.00 |
| Dec 31, 2020 | -52,086.00 |
| Sep 30, 2020 | 56,798.00 |
| Sep 30, 2020 | 56,798.00 |
| Jun 30, 2020 | 16,174.00 |
| Jun 30, 2020 | 16,174.00 |
| Mar 31, 2020 | 463,605.00 |
| Mar 31, 2020 | 463,605.00 |